Comparative Pharmacology
Head-to-head clinical analysis: ANTEPAR versus MINTEZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTEPAR versus MINTEZOL.
ANTEPAR vs MINTEZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Thiabendazole inhibits the mitochondrial fumarate reductase system in susceptible helminths, disrupting energy metabolism.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
50 mg/kg/day orally in 2-3 divided doses, maximum 3 g/day, for 2-3 days.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 2-8 hours (mean 4 hours). Hepatic impairment prolongs; dose adjustment recommended.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Renal: 90% within 24 hours (5% unchanged, 85% as metabolites). Fecal: <10%.
Category C
Category C
Anthelmintic
Anthelmintic